CN114903926B - 珊瑚树叶中Vibsane型总二萜及其制备方法和应用 - Google Patents
珊瑚树叶中Vibsane型总二萜及其制备方法和应用 Download PDFInfo
- Publication number
- CN114903926B CN114903926B CN202210479410.3A CN202210479410A CN114903926B CN 114903926 B CN114903926 B CN 114903926B CN 202210479410 A CN202210479410 A CN 202210479410A CN 114903926 B CN114903926 B CN 114903926B
- Authority
- CN
- China
- Prior art keywords
- vibsane
- coral
- type total
- leaves
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000014653 Carica parviflora Nutrition 0.000 title claims abstract description 65
- 241000243321 Cnidaria Species 0.000 title claims abstract description 65
- 150000004141 diterpene derivatives Chemical class 0.000 title claims abstract description 62
- 229930004069 diterpene Natural products 0.000 title claims abstract description 61
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000000284 extract Substances 0.000 claims abstract description 32
- 239000002904 solvent Substances 0.000 claims abstract description 25
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000000605 extraction Methods 0.000 claims abstract description 16
- 201000007270 liver cancer Diseases 0.000 claims abstract description 16
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 16
- 239000011347 resin Substances 0.000 claims abstract description 16
- 229920005989 resin Polymers 0.000 claims abstract description 16
- 239000000287 crude extract Substances 0.000 claims abstract description 15
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical group O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims abstract description 11
- 238000001179 sorption measurement Methods 0.000 claims abstract description 11
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 10
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 10
- 239000003208 petroleum Substances 0.000 claims abstract description 9
- 238000004440 column chromatography Methods 0.000 claims abstract description 8
- 238000010828 elution Methods 0.000 claims abstract description 7
- 238000001035 drying Methods 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 55
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 5
- 239000003560 cancer drug Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 10
- 238000000034 method Methods 0.000 abstract description 7
- 238000002474 experimental method Methods 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract description 2
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 238000011580 nude mouse model Methods 0.000 description 27
- 206010028980 Neoplasm Diseases 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 21
- 241000699660 Mus musculus Species 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 19
- 235000016678 Erythrina glauca Nutrition 0.000 description 16
- 240000008135 Piscidia piscipula Species 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 12
- 230000012010 growth Effects 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 7
- 239000008096 xylene Substances 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 239000002024 ethyl acetate extract Substances 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 229940041181 antineoplastic drug Drugs 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 125000000567 diterpene group Chemical group 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 3
- 239000003463 adsorbent Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 229960003787 sorafenib Drugs 0.000 description 3
- 238000002798 spectrophotometry method Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 241000208834 Adoxaceae Species 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000218218 Ficus <angiosperm> Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000208832 Viburnum Species 0.000 description 1
- 244000307537 Viburnum odoratissimum Species 0.000 description 1
- 235000013249 Viburnum odoratissimum Nutrition 0.000 description 1
- 235000019013 Viburnum opulus Nutrition 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- -1 diterpenoid compounds Chemical class 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000431 effect on proliferation Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种珊瑚树叶中Vibsane型总二萜及其制备方法和应用,属于植物医药技术领域。珊瑚树叶中Vibsane型总二萜的制备方法是将珊瑚树叶用提取溶剂提取,得到提取物;将提取物用石油醚萃取除油,并用乙酸乙酯萃取,去除溶剂,干燥,得到粗浸膏;将粗浸膏用大孔吸附树脂柱色谱进行梯度洗脱,洗脱溶剂为乙醇‑水溶液,收取90%馏分,去除洗脱溶剂,即为珊瑚树叶中Vibsane型总二萜。该制备方法工艺简单,成本低,可以工业化生产,且实验证实利用方法制得的Vibsane型总二萜具有明显的抗肝癌、乳腺癌活性,可以用于制备抗肿瘤药物,具备进一步开发为新药的潜力。
Description
技术领域
本发明涉及植物医药技术领域,涉及珊瑚树叶中Vibsane型总二萜及其制备方法和应用, 尤其涉及药用及园林作物珊瑚树叶中具有显著抗癌活性的Vibsane型总二萜的制备新方法。
背景技术
珊瑚树(Viburnum odoratissimum Ker-Gawl.var.odoratissimum)为五福花科(Adoxaceae)荚 蒾属(Viburnum)植物。其枝叶可入药,具有通经活络之功效,多用来消炎、止痛、抗风湿,为 民间传统用药。目前,从珊瑚树的枝叶中分离得到多种化学成分,其中,Vibsane型二萜类化 合物是珊瑚树中的特征化合物。该类化合物结构复杂,具有显著的抗癌活性。现有技术中,尽管已有报道表明Vibsane型二萜为珊瑚树中的主要活性成分,但精确分离活性显著的 Vibsane二萜单体流程复杂、成本高,同时得到的活性化合物含量较低,实际开发为药物的难 度较大。
发明内容
本发明的目的是提供一种珊瑚树叶中Vibsane型总二萜及其制备方法和应用,主要是提 供一种从珊瑚树叶中快速制备Vibsane型总二萜的制备方法,该制备方法工艺简单,成本低, 且实验证实利用方法制得的Vibsane型总二萜具有明显的抗肝癌、乳腺癌活性,可以用于制 备抗肿瘤药物,具备进一步开发为新药的潜力。
本发明的一种珊瑚树叶中Vibsane型总二萜的制备方法,包括以下步骤:
步骤1:
将珊瑚树叶用提取溶剂提取,得到提取物;
将提取物用石油醚萃取除油,并用乙酸乙酯萃取,去除溶剂,干燥,得到粗浸膏;
步骤2:
将粗浸膏用大孔吸附树脂柱色谱进行梯度洗脱,洗脱溶剂为乙醇-水溶液,收取90%馏分, 去除洗脱溶剂,即为珊瑚树叶中Vibsane型总二萜。
所述的步骤1中,珊瑚树叶为干燥的珊瑚树叶。
所述的步骤1中,提取采用的提取溶剂优选为甲醇或乙醇,甲醇或乙醇的体积浓度70~80%,提取次数优选为3~5次。
所述的步骤1中,去除溶剂优选为减压蒸馏。
所述的步骤1中,乙酸乙酯萃取时,按体积比,提取物:乙酸乙酯=1:(2~3)。
所述的步骤2中,大孔吸附树脂柱色谱中,大孔吸附树脂选用D-101大孔吸附树脂或 HP-20大孔吸附树脂中的一种。
所述的步骤2中,梯度洗脱采用的乙醇-水溶液中,乙醇的质量百分比梯度为30%,60%, 90%。
所述的步骤2中,去除洗脱溶剂采用减压蒸馏去除。
本发明的珊瑚树叶中Vibsane型总二萜,通过以上制备方法制得,其珊瑚树叶中Vibsane 型总二萜的Vibsane型总二萜的质量百分含量≥65%。
一种药物组合物,包含珊瑚树叶中Vibsane型总二萜和药学上可接受的载体或赋形剂。
本发明的珊瑚树叶中Vibsane型总二萜或药物组合物作为预防或治疗抗肿瘤药物的应用。
所述的抗肿瘤药物为抗肝癌药物或抗乳腺癌药物。
特别适用于,抑制体外肿瘤细胞生长的活性,更具体的肿瘤细胞为HepG2细胞株,Hep3B 细胞株,MCF-7细胞株。
其中,抗肿瘤药物中珊瑚树叶中Vibsane型总二萜作用于HepG2细胞株的IC50值为11.11~11.21μg/mL,抗肿瘤药物中珊瑚树叶中Vibsane型总二萜作用于Hep3B细胞株的IC50值为9.64~9.82μg/mL,抗肿瘤药物中珊瑚树叶中Vibsane型总二萜作用于MCF-7细胞株的IC50值为14.62~15.74μg/mL。
珊瑚树叶中Vibsane型总二萜或药物组合物,适用于体内抗癌活性。在两周的给药时间 内,低剂量组珊瑚树叶中Vibsane型总二萜(100mg/kg)使裸鼠移植Hep3B肿瘤的体积缩小55% 以上,高剂量组珊瑚树叶中Vibsane型总二萜(200mg/kg)使裸鼠移植Hep3B肿瘤的体积缩小 75%以上,优于阳性药索拉菲尼的40%,能够显著抑制裸鼠移植Hep3B肿瘤的生长,且未表 现出明显毒性。
本发明的一种珊瑚树叶中Vibsane型总二萜及其制备方法和应用,其有益效果在于:
珊瑚树叶的Vibsane型总二萜具有比珊瑚树叶总提物更强的肝癌、乳腺癌细胞的抑制活 性,并且可以抑制裸鼠移植HepG2、Hep3B、MCF-7肿瘤的生长。
本发明采用移植肝癌Hep3B细胞株的裸鼠模型对珊瑚树叶的Vibsane型总二萜的体内抗 肝癌活性进行测试。结果表明,珊瑚树叶的Vibsane型总二萜能够抑制肝癌、乳腺癌的增殖 并抑制人肝癌Hep3B裸鼠移植瘤的生长。毒性评估表明本发明所描述的珊瑚树叶Vibsane型总二萜对小鼠各脏器未表现出明显毒性。因此,本发明所述的珊瑚树叶的Vibsane型总二萜 的抗癌作用安全有效,具有进一步开发为临床抗肝癌、乳腺癌预防和治疗药物的前景。
本发明的制备方法设计合理,具有过程工艺简单,可工业化生产的特点。
附图说明
图1为人肝癌Hep3B裸鼠肿瘤体积随给药量的变化情况;(a)在体裸鼠肿瘤;(b)为离体 裸鼠肿瘤。
图2为不同给药量下,小鼠肿瘤体积随时间的变化曲线。
图3为不同给药量下,小鼠肿瘤大小的变化情况图。
图4为不同给药量下,小鼠体重随时间变化曲线。
图5为小鼠心、肝、脾、肺、肾随给药量的变化情况图。
图6为赫斯特(H&E)染色结果。
图7为免疫组织化学分析结果图。
具体实施方式
下面结合实施例对本发明作进一步的详细说明。
实施例1
一种珊瑚树叶中Vibsane型总二萜的制备方法,包括以下步骤:
取干燥珊瑚树叶1kg,用75%甲醇或乙醇提取3~5次,减压浓缩得到珊瑚树叶总提物; 将所得珊瑚树叶粗提物经石油醚萃取除油,除去脂肪酸等小极性成分;随后经乙酸乙酯以珊 瑚树叶提取物:乙酸乙酯萃取液1:2的体积比例萃取3次,合并经减压浓缩得乙酸乙酯层总 浸膏。以HP-20经乙醇-水系统以30%、60%、90%的乙醇质量浓度比例进行洗脱,每个比例 洗脱4~6个保留体积,回收溶剂,对90%流分减压浓缩得到珊瑚树叶中Vibsane型总二萜浸 膏4.92g。利用紫外-可见光分光光度法,以15-O-methylvibsanin H为对照品,在230.5nm的 波长处,配置标准曲线并测定吸光度,检测结果显示所得珊瑚树叶Vibsane型总二萜得含量为70.521%。
实施例2
一种珊瑚树叶中Vibsane型总二萜的制备方法,包括以下步骤:
取干燥珊瑚树叶1kg,用75%甲醇或乙醇提取3~5次,减压浓缩得到珊瑚树叶总提物;将所得珊瑚树叶粗提物经石油醚萃取除油;随后经乙酸乙酯以珊瑚树叶提取物:乙酸乙酯萃 取液1:2的体积比例萃取3次,合并经减压浓缩得乙酸乙酯层总浸膏。以HP-20经乙醇-水 系统以30%、60%、90%的乙醇质量浓度比例进行洗脱,每个比例洗脱4~6个保留体积,回 收溶剂,对90%流分减压浓缩得到珊瑚树叶中Vibsane型总二萜浸膏4.46g。利用紫外-可见光 分光光度法,以15-O-methylvibsanin H为对照品,在230.5nm的波长处,配置标准曲线并测 定吸光度,检测结果显示所得珊瑚树叶Vibsane型总二萜得含量为72.436%。
实施例3
取干燥珊瑚树叶1kg,用75%甲醇或乙醇提取3~5次,减压浓缩得到珊瑚树叶总提物; 将所得珊瑚树叶粗提物经石油醚萃取除油;随后经乙酸乙酯以珊瑚树叶提取物:乙酸乙酯萃 取液1:2的体积比例萃取3次,合并经减压浓缩得乙酸乙酯层总浸膏。以HP-20经乙醇-水 系统以30%、60%、90%的乙醇质量浓度比例进行洗脱,每个比例洗脱4~6个保留体积,回 收溶剂,对90%流分减压浓缩得到珊瑚树叶中Vibsane型总二萜浸膏4.66g。利用紫外-可见光 分光光度法,以15-O-methylvibsanin H为对照品,按照此方法制备的珊瑚树叶Vibsane型总 二萜含量以标准曲线法,在230.5nm的波长处,配置标准曲线并测定吸光度,检测结果显示所得珊瑚树叶Vibsane型总二萜得含量为69.268%。
实施例4
一种珊瑚树叶中Vibsane型总二萜的制备方法,包括如下步骤:
将珊瑚树叶日光下晒干,用体积浓度为80%甲醇提取,减压浓缩得到珊瑚树叶提取物; 提取次数为:4次;
将所得的珊瑚树叶提取物用石油醚萃取,除去脂肪酸等小极性成分;
将粗提物进一步用乙酸乙酯以珊瑚树叶提取物:乙酸乙酯萃取液1:2的体积比例进行萃 取,重复三次并合并,减压回收溶剂;
将乙酸乙酯萃取所得粗提物利用D-101大孔吸附树脂柱色谱以乙醇-水中,乙醇的质量浓 度为30%、60%、90%进行梯度洗脱得到三个流分A1、A2、A3;
对流分A3减压回收溶剂,即得到Vibsane二萜含量较高得粗流分。
实施例5
一种珊瑚树叶中Vibsane型总二萜的制备方法,包括如下步骤:
将珊瑚树叶日光下晒干,用体积浓度为75%甲醇提取,减压浓缩得到珊瑚树叶提取物; 提取次数为:3次;
将所得的珊瑚树叶提取物用石油醚萃取,除去脂肪酸等小极性成分;
将粗提物进一步用乙酸乙酯以珊瑚树叶提取物:乙酸乙酯萃取液1:3的体积比例进行萃 取,重复三次并合并,减压回收溶剂;
将乙酸乙酯萃取所得粗提物利用HP-20大孔吸附树脂柱色谱以乙醇-水中,乙醇的质量浓 度为30%、60%、90%进行梯度洗脱得到三个流分A1、A2、A3;
对流分A3减压回收溶剂,即得到Vibsane二萜含量较高得粗流分。
实施例6
一种珊瑚树叶中Vibsane型总二萜的制备方法,包括如下步骤:
将珊瑚树叶日光下晒干,用体积浓度为80%乙醇提取,减压浓缩得到珊瑚树叶提取物; 提取次数为:4次;
将所得的珊瑚树叶提取物用石油醚萃取,除去脂肪酸等小极性成分;
将粗提物进一步用乙酸乙酯以珊瑚树叶提取物:乙酸乙酯萃取液1:2的体积比例进行萃 取,重复三次并合并,减压回收溶剂;
将乙酸乙酯萃取所得粗提物利用D-101大孔吸附树脂柱色谱以乙醇-水中,乙醇的质量浓 度为30%、60%、90%进行梯度洗脱得到三个流分A1、A2、A3;
对流分A3减压回收溶剂,即得到Vibsane二萜含量较高得粗流分,即为。
应用例1
用实施例1~3制备得到的珊瑚树叶Vibsane型总二萜,对人肝癌HepG2,Hep3B及人乳腺 癌MCF-7细胞增殖有明显的抑制作用。
采用改良MTT法:将融合为单层的HepG2、Hep3B和MCF-7肿瘤细胞消化为单细胞 悬浮液,加入96孔培养板中,90μL/孔。在37℃、5%CO2培养箱中孵育24h后,加入一 定浓度的受试样品,10μL/孔。受试样品组设置3个复孔。阴性对照为等体积的PBS,阳性 对照为顺铂(DDP),继续孵育48小时后,每孔加入10μl的MTT溶液5mg/ml,10μL/孔, 避光37℃孵育2-4h;每孔加入100μl的MTT溶解buffer(20%SDS,1M HCl),37℃孵育 至结晶完全溶解;利用全自动酶标仪读取570nm及490nm处的吸光度,计算OD(570) -OD(490)的数值作为每孔的OD值;根据以下公式计算计算相对抑制率:细胞相对抑制 率(%)=100%-(实验组OD值/对照组平均OD值)×100%。用SPSS12.0软件计算各样 品的IC50值,结果见表1。
表1本发明Vinsane型总二萜对三种肿瘤细胞的抑制作用
应用例2
用实施例4~6制备得到的珊瑚树叶Vibsane型总二萜,对人肝癌HepG2,Hep3B及人乳腺 癌MCF-7细胞增殖有明显的抑制作用。
所述的珊瑚树叶的Vibsane型总二萜具有比珊瑚树叶总提物更强的肝癌、乳腺癌细胞的 抑制活性,并且可以抑制裸鼠移植HepG2、Hep3B、MCF-7肿瘤的生长。
采用改良MTT法,测试珊瑚树叶的Vibsane型总二萜对人肝癌HepG2细胞株,Hep3B细胞株及乳腺癌MCF-7细胞株的体外抗肿瘤作用进行评估。实验结果表明珊瑚树叶的Vibsane 型总二萜在体外对上述三种细胞株具有显著的细胞增殖抑制活性,IC50值分别为11.11μg/ml, 9.64μg/ml,14.62μg/ml(见表2)。
表2珊瑚树总提物与Vibsane型总二萜对多种肿瘤细胞抑制作用的考察。
通过表2说明Vibsane型总二萜对肿瘤细胞的抑制作用具有选择性,并非对所有肿瘤细 胞都均有抑制作用。
实施例5
用实施案列1~3制备得到的Vibsane型总二萜,对人肝癌Hep3B裸鼠移植瘤的生长具有 明显的抑制作用。
取对数生长期Hep3B细胞,经胰酶消化后离心收集细胞,用PBS清洗一次后同转速再次 离心,对得到的细胞采用无血清DMEM配成细胞悬液并控制细胞密度为1×107/mL。所用动 物为SPF级BALB/c无胸腺裸鼠,雄性,6-8周龄,体重18-22g。实验育种严格遵守SPF级标准的要求。在无菌条件下,用1mL胰岛素针向每只裸鼠背后右侧前肢皮下旁进行注射Hep3B细胞悬液0.2mL。注射后每日观测裸鼠状况和皮下的肿瘤生长情况,当裸鼠皮下出现粟粒大小的结节时表示裸鼠模型构建成功。当肿瘤体积大约到100mm3时,将5只小鼠随机分配为一组,共4组。低剂量组为100mg/kg的Vibsane型总二萜,高剂量为200mg/kg的Vibsane型总二萜,阳性药组为30mg/kg的索拉非尼,对照组注射相同体积的生理盐水,均采用灌胃给药的方式,每2天一次,连续给药2周。结果表明经低剂量组及高剂量组Vibsane二萜给药后,小鼠肿瘤体积随时间显著减小,说明Vibsane型总二萜对人肝癌Hep3B裸鼠移植瘤的生长具有明显的抑制作用(图1、图2和图3)。
每次裸鼠给药前均观察并记录各组裸鼠体重、摄食、饮水、活动能力、大便形态、精神 状态、反应及接种部位移植瘤的生长情况。给药期间,每天需用游标卡尺测量裸鼠肿瘤长径 (L)和短径(W),肿瘤体积计算公式:V=0.5236×L×W2,并分别计算四组肿瘤的平均体 积,数据表示为mean±SD,并绘制为肿瘤生长随时间变化曲线。待药物干预2周后停止实验并按公式抑瘤率(%)=[(V(control group)-V(drug groups))/V(control group)]×100%计算肿 瘤体积与肿瘤生长抑制率。实验结果表明,与索拉菲尼对照组相比,Vibsane型总二萜干预期间裸鼠体重无显著改变(图4)。
化合物作用结束后,每只裸鼠腹腔注射1mL 10%水合氯醛进行深度麻醉处死并拍照。用 消毒后的手术器械将移植瘤完整剥离,取出每只裸鼠的重要器官(心、肝、脾、肺、肾),用电子分析天平称重、记录。取出的肿瘤及器官组织用0.85%生理盐水漂洗以洗去血液及物质, 然后用手术刀切成适当的组织块。将每组每只裸鼠的肿瘤及器官组织分成两份,一份浸泡于 10%中性福尔马林溶液固定(组织块体积与10%中性福尔马林溶液体积的比例约为1:20),另 一份包装好后置于-80℃长期保存,并做好标记(图5)。将裸鼠脏器组织浸没于4%中性福尔马 林中固定,将固定好的脏器组织放置于包埋盒中,放入组织自动脱水机上,经梯度酒精(70%、 80%、90%、95%和100%)脱水。经透明及充分浸蜡后,对组织进行包埋并切片,石蜡切片 厚度为5μm。65℃烤箱烘烤3h,常温保存,备用。依次将切片放入二甲苯Ⅰ10min,二甲 苯Ⅱ10min,无水乙醇Ⅰ5min,无水乙醇Ⅱ5min,95%乙醇5min,90%乙醇5min,80%乙醇5min,70%乙醇5min,蒸馏水洗。切片入Harris苏木素染3-8min,自来水洗,1%的 盐酸酒精分化数秒,自来水冲洗,0.6%氨水返蓝,流水冲洗。切片入伊红染液中染色1-3min。 紧接着将切片依次放入95%乙醇I 5min,95%乙醇II 5min,无水乙醇Ⅰ5min,无水乙醇Ⅱ5 min,二甲苯Ⅰ5min,二甲苯Ⅱ5min中脱水透明,将切片从二甲苯拿出来稍晾干,中性树 胶封片,在显微镜下观察(图6)。结果表明Vibsane型总二萜流分对裸鼠的心肝脾肺肾无明显 的影响。
将裸鼠脏器组织浸没于4%中性福尔马林中固定,将固定好的脏器组织放置于包埋盒中, 放入组织自动脱水机上,经梯度酒精(70%、80%、90%、95%和100%)脱水。经透明及充 分浸蜡后,对组织进行包埋并切片,石蜡切片厚度为5μm。65℃烤箱烘烤3h,常温保存,备用。首先进行将石蜡切片置于摊片机上,50-60℃,摊片40-50min,用于固定切片上的病 理组织。按如下步骤进行脱蜡:二甲苯Ⅰ(20min),二甲苯Ⅱ(20min),100%乙醇Ⅰ(10min)100%乙醇Ⅱ(10min),95%的乙醇(5min),85%乙醇(5min),75%乙醇(5min),蒸馏水 洗3次(3min),PBS缓冲液清洗3次(3min)。每张组织切片加一滴过氧化酶阻断溶液(3% H2O2)37℃孵育20min,PBS缓冲液洗片3次,每次5min;组织切片在柠檬酸盐缓冲液中 加热以进行抗原修复。然后,在室温下用正常山羊血清处理切片20min。并在4℃下用一级 抗体孵育过夜。组织切片室温复温45min,回收一抗,PBS缓冲液洗片3次(5min);每张 组织切片滴加一滴生物素标记的山羊抗鼠IgG二抗,37℃孵育30min,甩去二抗,PBS缓冲 液洗片3次(5min);甩去PBS缓冲液,每张组织切片滴加一滴链霉素抗生物素-过氧化物酶 溶液,37℃孵育30min,PBS缓冲液洗片3次,每次5min;最后,用DAB染色,用中性树 脂密封,自然风干,在显微镜下观察。抗体包括Ki67、Bax、p-AKT(图7)。结果表明Bax阳 性比例明显增加,Ki67以及p-AKT的阳性比例下降,表明Vibsane型总二萜可以明显抑制 Hep3B细胞异种移植模型的生长。
综合以上分析结果表明,Vibsane型总二萜可以明显的抑制Hep3B裸鼠移植瘤的体积和 大小,且对小鼠体重及主要脏器物明显影响,在体内安全有效。
Claims (1)
1.一种珊瑚树叶中Vibsane型总二萜在制备抗肝癌、抗乳腺癌药物中的应用,其特征在于,所述珊瑚树叶中Vibsane型总二萜的制备方法,包括以下步骤:
步骤1:
将珊瑚树叶用提取溶剂提取,得到提取物;采用的提取溶剂为甲醇或乙醇,甲醇或乙醇的体积浓度70~80%,提取次数为3~5次;
将提取物用石油醚萃取除油,并用乙酸乙酯萃取,去除溶剂,干燥,得到粗浸膏;乙酸乙酯萃取时,按体积比,提取物:乙酸乙酯=1:(2~3);
步骤2:
将粗浸膏用大孔吸附树脂柱色谱进行梯度洗脱,大孔吸附树脂柱色谱中,大孔吸附树脂选用D-101大孔吸附树脂或HP-20大孔吸附树脂中的一种,洗脱溶剂为乙醇-水溶液,梯度洗脱采用的乙醇-水溶液中,乙醇的质量百分比梯度为30%,60%,90%,收取90%馏分,去除洗脱溶剂,即为珊瑚树叶中Vibsane型总二萜;
所述珊瑚树叶中Vibsane型总二萜的Vibsane型总二萜的质量百分含量≥65%。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210479410.3A CN114903926B (zh) | 2022-05-05 | 2022-05-05 | 珊瑚树叶中Vibsane型总二萜及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210479410.3A CN114903926B (zh) | 2022-05-05 | 2022-05-05 | 珊瑚树叶中Vibsane型总二萜及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114903926A CN114903926A (zh) | 2022-08-16 |
CN114903926B true CN114903926B (zh) | 2024-01-30 |
Family
ID=82767189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210479410.3A Active CN114903926B (zh) | 2022-05-05 | 2022-05-05 | 珊瑚树叶中Vibsane型总二萜及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114903926B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115974695B (zh) * | 2022-12-13 | 2024-05-03 | 沈阳药科大学 | 珊瑚树中降vibsane二萜类化合物的制备方法及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105061456A (zh) * | 2015-09-13 | 2015-11-18 | 周午贤 | 一种新的贝壳杉烷类二萜化合物及其制备方法和医药用途 |
CN105237415A (zh) * | 2015-05-18 | 2016-01-13 | 中国科学院昆明植物研究所 | Vibsanin B衍生物及其药物组合物和其在制药中的应用 |
CN108653368A (zh) * | 2018-07-24 | 2018-10-16 | 启东创潞新材料有限公司 | 一种珊瑚树萜类成分的制备方法 |
CN114195641A (zh) * | 2020-09-18 | 2022-03-18 | 沈阳药科大学 | 七元vibsane二萜类化合物及其制备和应用 |
-
2022
- 2022-05-05 CN CN202210479410.3A patent/CN114903926B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105237415A (zh) * | 2015-05-18 | 2016-01-13 | 中国科学院昆明植物研究所 | Vibsanin B衍生物及其药物组合物和其在制药中的应用 |
CN105061456A (zh) * | 2015-09-13 | 2015-11-18 | 周午贤 | 一种新的贝壳杉烷类二萜化合物及其制备方法和医药用途 |
CN108653368A (zh) * | 2018-07-24 | 2018-10-16 | 启东创潞新材料有限公司 | 一种珊瑚树萜类成分的制备方法 |
CN114195641A (zh) * | 2020-09-18 | 2022-03-18 | 沈阳药科大学 | 七元vibsane二萜类化合物及其制备和应用 |
Non-Patent Citations (8)
Title |
---|
Diterpenes and lignans from Viburnum odoratissimum var. odoratissimum;Feng-Jie Li等;Journal of Asian Natural Products Research;第1-7页 * |
Identification of vibsanin A analog as a novel HSP90 inhibitor;Kazuki Miura等;Bioorganic & Medicinal Chemistry;第28卷(第2期);第115253页,尤其是第1个表格内容 * |
Shi-Fang Li等.Vibsane-type diterpenoids from Viburnum odoratissimum and their cytotoxic activities.Bioorganic Chemistry.2020,第106卷第104498页,尤其是第2页第2.3节,第8页右栏第3段及表3. * |
Vibsane-type diterpenoids from Viburnum odoratissimum and their cytotoxic activities;Shi-Fang Li等;Bioorganic Chemistry;第106卷;第104498页,尤其是第2页第2.3节,第8页右栏第3段及表3 * |
Vibsane-Type Diterpenoids from Viburnum odoratissimum and Their Cytotoxic and HSP90 Inhibitory Activities;Qin-Feng Zhu等;Chem. Biodiversity;第15卷;第1800049页,尤其是摘要、结果讨论、表3 * |
珊瑚树 Vibsane 型二萜类化合物对人体 HepG2 细胞增殖的影响及其机制;张海芳等;中国应用生理学杂志;第30卷(第4期);第343-347页 * |
珊瑚树化学成分及生物活性研究进展;刘洁等;药学学报;第48卷(第3期);第325−332页 * |
赵运林等.湖南药用植物资源.湖南科学技术出版社,2009,(第1版),第730页. * |
Also Published As
Publication number | Publication date |
---|---|
CN114903926A (zh) | 2022-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5135745A (en) | Extracts of nerium species, methods of preparation, and use therefore | |
Gürbüz et al. | In vivo gastroprotective effects of five Turkish folk remedies against ethanol-induced lesions | |
Yesilada et al. | Anti-ulcerogenic activity and isolation of the active principles from Sambucus ebulus L. leaves | |
KR101762750B1 (ko) | 무궁화의 꽃으로부터 추출된 정유를 포함하는 피부 재생용 외용제 및 화장료 조성물 | |
CN103222988B (zh) | 一种美洲大蠊提取物及其制备方法和应用 | |
Pleskanovskaya et al. | Glycyrrhiza glabra (licorice) in Turkmenistan: medicinal and biological aspects | |
CN114903926B (zh) | 珊瑚树叶中Vibsane型总二萜及其制备方法和应用 | |
WO2010028075A1 (en) | Herbal composition for treating cancer | |
US20030232102A1 (en) | Total glycosides of paeony, method to prepare the same and uses thereof | |
CN102335211A (zh) | 穿心莲提取物及其化学成份在制备治疗病理性血管新生疾病的药物中的应用 | |
He et al. | Network pharmacology unveils spleen-fortifying effect of Codonopsis Radix on different gastric diseases based on theory of “same treatment for different diseases” in traditional Chinese medicine | |
CN107213145B (zh) | 细锥香茶菜乙素在制备抑制食管鳞癌细胞增殖的产品中的应用 | |
CN106177187B (zh) | 具有增效减毒抗肝癌作用的茶多酚茶多糖组合物 | |
US7229652B2 (en) | Extract from the leaves of Toona sinensis Roem., and the preparation process and uses thereof | |
EP0246069B1 (en) | Extracts of nerium species, methods of preparation, and use therefore | |
CN102006880A (zh) | 葡萄籽萃取物的制备方法及含该萃取物的用于预防或治疗类风湿性关节炎的药物组合物 | |
CN111150752A (zh) | 鸡骨草提取物在制备抗癌药物中的应用 | |
CN106117034A (zh) | 一种高度氧化的倍半萜类化合物及其制备方法和医药用途 | |
CN104840747B (zh) | 具有抗甲状腺癌活性的中药组合物及其制备方法和应用 | |
CN103497871A (zh) | 一种养血、滋阴保健酒的组配方法 | |
CN104666779B (zh) | 一种治疗非小细胞肺癌的药物及其制备方法 | |
CN107648221A (zh) | 大萼香茶菜乙素二乙酰化物的药物新用途 | |
CN109662970B (zh) | 一种羊毛甾烷型的应用 | |
CN1961911A (zh) | 一种含丹参和降香挥发油的冻干粉针及其制备方法 | |
CN112274557A (zh) | 冬凌草叶水提物粉末,其制备,抗动脉血栓作用及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |